SODA NIKKA (8158) FY2026 Q3 Earnings Report

Quick View

Executive Summary

The results showed higher revenue and double-digit increases in operating income and ordinary income, while net income remained almost flat. Revenue was ¥501.4B (+2.5% YoY), operating income was ¥19.4B (+13.3%), ordinary income was ¥23.7B (+15.1%), and net income was ¥18.5B (at the same level as the previous year). The increase in operating income was driven by expanded orders for chemicals for the electronics industry and water-treatment agents for municipalities in the Chemicals Business, while the slowdown in net income growth was primarily attributable to a decline in gains on the sale of investment securities recorded in the previous year (¥7.05B in the previous year → ¥4.15B in the current period).

Factors Affecting Performance

【Revenue】Revenue was ¥501.4B, representing a +2.5% YoY increase. The core Chemicals Business increased revenue by +1.9%, supported by higher sales of soda-related chemicals to the electronics industry and new orders for aluminum compounds from municipalities. The Functional Materials Business also increased revenue by +5.2%, driven by overseas orders for packaging-related equipment and growth in sales of composite films for food packaging.

【Profit and Loss】Operating income was ¥19.4B (+13.3%), and the operating margin improved to 3.9% from the previous year. Ordinary income was ¥23.7B (+15.1%), with dividend income of ¥4.5B accounting for the majority of non-operating income and contributing to the increase. Although a gain on the sale of investment securities of ¥4.2B was recorded as extraordinary income, this declined from ¥7.1B in the previous year, leaving net income almost flat at ¥18.5B. The effective tax rate was 33.1%, in line with normal levels. In conclusion, these were results characterized by clear improvement in earnings power from operating activities, with both revenue and profits increasing; the slowdown in net income growth was primarily an accounting-related factor resulting from the decline in temporary extraordinary income.

Segment Analysis

By revenue composition, Chemicals (Chemicals Business) generated ¥335.4B, accounting for 66.9% of total revenue, and is positioned as the core business. Operating income from this business was ¥29.2B, with a margin of 8.7%, exceeding the performance of FunctionalMaterials (Functional Materials Business; revenue of ¥115.1B, operating income of ¥6.3B, and margin of 5.5%). The core Chemicals Business generated 82.2% of total operating income (¥35.6B). The primary driver of profit growth was also the expansion of orders for the Chemicals Business from the electronics and municipal sectors, while overseas packaging-related equipment projects in the Functional Materials Business made a supplementary contribution. The difference in profit margins between the two businesses (8.7% versus 5.5%) indicates the relatively higher value-added nature of the products handled by the Chemicals Business.

Key Financial Indicators

Profitability: ROE was 5.6% (cumulative quarterly basis), and the operating margin was 3.9% (3.5% in the previous year).
Financial soundness: The equity ratio was 39.4% (down from 40.3% in the previous year). Current assets were ¥582.1B versus current liabilities of ¥453.2B, resulting in a current ratio of approximately 128%.
Asset composition: Accounts receivable of ¥467.6B accounted for 55.8% of total assets, while investment securities of ¥175.7B increased by +27.3% YoY.

Cash Flow Analysis

This material does not disclose a statement of cash flows, and specific figures for operating cash flow (OCF), investing cash flow, and financing cash flow cannot be confirmed. Given the substantial increase in accounts receivable (+¥51.6B YoY), the actual level of cash generation relative to profit growth requires confirmation, including trends in working capital.

Earnings Quality

The difference between ordinary income of ¥23.7B and net income of ¥18.5B was primarily attributable to the ¥9.2B burden of income taxes and other taxes. The effective tax rate against pretax income after deducting extraordinary gains and losses of ¥27.6B was 33.1%. Of non-operating income of ¥4.8B, dividend income amounted to ¥4.5B, or 93.8%, and represented approximately 0.9% of revenue. Accordingly, its contribution to ordinary income was limited but it constitutes a stable source of earnings. The gain on the sale of investment securities of ¥4.2B recorded as extraordinary income was a non-recurring item, and its decline from ¥7.1B in the previous year directly contributed to the slowdown in net income growth. Excluding this temporary factor, underlying earnings growth is considered to be close to the growth rates of operating income and ordinary income.

Earnings Forecast and Guidance

The full-year forecasts remain unchanged from the initial forecasts, at revenue of ¥705.0B, operating income of ¥23.4B, and ordinary income of ¥26.7B. The cumulative Q3 progress rates were 71.1% for revenue, 82.7% for operating income, and 88.8% for ordinary income. While profit progress exceeded the standard level of 75%, revenue progress was below that level. This divergence suggests that profitability improvement in the Chemicals Business is progressing at a faster pace than revenue growth, making a recovery in the pace of revenue growth a key issue for Q4.

Shareholder Returns

The Company plans to pay ¥20 per share as an interim dividend and ¥20 per share as a year-end dividend, for an annual dividend of ¥40, and continues its policy of establishing a regular payout ratio of 40% or more. The forecast payout ratio against full-year forecast EPS of ¥101.01 is approximately 39.6%, broadly consistent with the policy. No disclosure regarding share repurchases has been made, and shareholder returns are evaluated solely on the basis of dividends.

Catalysts

【Short Term】Order trends in Q4 for water-treatment agents for municipalities and inorganic chemicals for the electronics industry in the Chemicals Business, as well as the recovery in the revenue progress rate. 【Long Term】Continued implementation of the policy of establishing a regular payout ratio of 40% or more under the medium-term management plan “Go forward STAGE3,” and the accumulation of overseas packaging-related equipment projects in the Functional Materials Business.

Industry Benchmark (For Reference; Company Analysis)

Industry Benchmark (trading)

Profitability and Returns

The Company's profitability is slightly above the industry median.

Growth and Capital Efficiency

The revenue growth rate is below the industry median, indicating relatively moderate growth.

※Source: Company analysis

Risk Factors

1. Accounts Receivable Collection Risk: Accounts receivable of ¥467.6B accounted for 55.8% of total assets and increased by +¥51.6B YoY. A lengthening collection period could affect cash management.

2. Low-Margin Structure: With a gross margin of 14.4% and an operating margin of 3.9%, the Company has the low-margin structure characteristic of distribution and trading-company businesses. Accordingly, fluctuations in procurement prices and logistics costs have a relatively significant impact on profitability.

3. Business Environment for Overseas Subsidiaries: The overseas consolidated subsidiary in Indonesia is facing difficulties in chemical sales due to an economic slowdown and changes in the competitive environment, acting as a partial downward factor for other businesses.

Key Points from the Earnings Results

1. The operating margin improved to 3.9% from 3.5% in the previous year, indicating progress in profitability improvement centered on the Chemicals Business. Meanwhile, the reason net income growth was limited to +0.1% was the decline in gains on the sale of investment securities, making it important to distinguish this from profit growth generated by operating activities.

2. While the full-year progress rates for operating income and ordinary income, at 82.7% and 88.8%, respectively, exceeded the standard level, the revenue progress rate was below that level at 71.1%. This indicates a structure in which profit growth depends more on profitability improvement than on volume expansion.

3. Under the policy of establishing a regular payout ratio of 40% or more, the forecast payout ratio is approximately 39.6%, nearly in line with the policy, while full-year profit progress is also at a level that supports the dividend.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,309–¥1,385 at ±1% for the cost of equity, and ¥1,343–¥1,348 at ±0.1 for ω.

Notes:

• As forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated at a somewhat high level.

(Calculation model: Residual income model (Ohlson type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through an integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and, where necessary, after consulting with a professional advisor.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was operationally stronger, with revenue growth translating into double-digit operating and ordinary-income growth, while bottom-line growth was held back by a smaller securities-sale gain. Revenue increased 2.5% YoY to ¥50.14bn. Operating income increased 13.3% to ¥1.94bn, materially outpacing sales growth. Ordinary income grew 15.1% to ¥2.37bn. The operating margin expanded by 37bp YoY to 3.9% from 3.5%. Gross margin improved by 40bp to 14.4% from 14.0%, indicating modestly improved trading profitability. Gross profit rose 5.6% to ¥7.22bn, exceeding the 3.0% increase in SG&A expenses to ¥5.29bn. Salaries and allowances were broadly stable at ¥1.82bn, rising only 0.8% YoY. This cost discipline supported positive operating leverage despite the low-margin nature of the chemical trading business. Net income was essentially flat at ¥1.85bn, up only 0.1% YoY. The principal reason for the divergence from operating growth was a ¥290mn YoY decline in gain on sale of investment securities, to ¥415mn. Dividend income increased to ¥451mn and represented the bulk of non-operating income, making investment income an important contributor to ordinary profit. Comprehensive income rose sharply to ¥4.44bn, supported by a ¥2.63bn positive valuation difference on securities. Equity increased ¥3.50bn YoY to ¥33.04bn, aided by retained earnings and unrealized securities valuation gains. The full-year operating-income forecast of ¥2.34bn is 82.7% achieved at Q3, 7.7 percentage points ahead of the standard 75% seasonal benchmark. The ordinary-income forecast is 88.8% achieved, 13.8 percentage points ahead of the benchmark, although this incorporates dividend income and other non-operating contributions. The full-year net-income forecast is 80.3% achieved, leaving a more moderate ¥452mn of Q4 earnings implied. The key forward implication is that core operating momentum supports forecast delivery, but profitability remains structurally constrained by low gross and operating margins and high working-capital intensity.

Profitability Analysis

Annualized DuPont ROE is 7.5%, comprising a 3.7% net profit margin, 0.798x asset turnover, and 2.54x financial leverage. The principal constraint on shareholder returns is the thin net margin, while leverage makes a meaningful contribution to ROE. The 3.9% EBIT margin is below the 5% efficiency threshold and reflects the low-margin characteristics of chemical distribution and trading operations. Gross margin improved 40bp YoY to 14.4%, and operating margin improved 37bp to 3.9%, demonstrating that incremental gross profit exceeded incremental SG&A. SG&A increased 3.0% YoY, slightly faster than sales growth of 2.5%, but gross profit growth of 5.6% more than offset that modest negative cost leverage. Operating income growth of 13.3% therefore appears primarily driven by margin improvement rather than volume-led sales expansion. Net margin declined by approximately 9bp YoY to 3.7%, because the prior-year period contained a larger ¥705mn gain on sale of investment securities versus ¥415mn in FY2026 Q3. The tax burden was 0.668, corresponding to a 33.1% effective tax rate, and was moderately less favorable than a normal tax-burden benchmark above 0.70. The interest burden exceeded 1.0x because profit before tax benefited from non-operating and extraordinary income; it should not be interpreted as operating earnings being inherently more than sufficient to cover financing costs. Interest coverage was very strong at 55.29x, with interest expense of only ¥35mn. Dividend income of ¥451mn, equal to 23.2% of operating income, is a material supplement to operating earnings. Sustainability of current ROE therefore depends on maintaining the gross-margin improvement, disciplined overhead growth, and stable investment-income contribution.

Growth Assessment

Sales growth of 2.5% was modest, but the conversion of that growth into 13.3% operating-income growth was favorable. Gross profit grew ¥382mn YoY, while SG&A rose by ¥154mn, producing a ¥227mn increase in operating income. This indicates improved spread capture and a favorable gross-profit mix, although the 14.4% gross margin remains low in absolute terms. Ordinary income grew ¥312mn, faster than operating income, as dividend income rose ¥51mn and non-operating expenses declined. Profit before tax was essentially unchanged at ¥2.77bn because the securities-sale gain declined by ¥290mn YoY. Consequently, net income remained flat despite the improved underlying operating result. Full-year sales guidance of ¥70.50bn is 71.1% achieved at Q3, 3.9 percentage points below the standard 75% progress rate. Operating-income guidance is 82.7% achieved, indicating that the company has already built a cushion against the ¥2.34bn target. Ordinary income is 88.8% achieved, exceeding the standard pace by 13.8 percentage points. Forecast net income of ¥2.30bn is 80.3% achieved, implying Q4 net income of approximately ¥452mn. The Q4 implied operating income is approximately ¥405mn, below the Q1-Q3 cumulative quarterly average of ¥645mn, suggesting that the operating forecast appears achievable if current trading conditions remain broadly stable. The more conservative sales progress versus profit progress indicates that the outlook is more dependent on maintaining margins and investment returns than on accelerating top-line growth.

Financial Health

Liquidity is adequate, with a current ratio of 128.4% and a quick ratio of 125.0%. Current assets of ¥58.21bn exceed current liabilities of ¥45.32bn, generating working capital of ¥12.88bn. Cash and deposits of ¥8.96bn cover short-term loans of ¥3.66bn by 2.45x. Interest-bearing debt is limited relative to capital, with debt/capital of 10.0% and interest-bearing debt representing approximately 0.11x total equity. The reported debt-to-equity ratio of 1.54x remains below the 2.0x aggressive-leverage warning level, although the balance sheet is naturally liability-intensive because trade payables account for ¥39.24bn. The principal maturity consideration is that 100% of interest-bearing debt is short term. This creates refinancing risk because ¥3.66bn of borrowing requires ongoing rollover, even though cash coverage and interest coverage are currently strong. Trade receivables of ¥46.77bn account for 55.8% of total assets, while trade payables account for 77.2% of total liabilities. This structure is consistent with a trading business but leaves liquidity sensitive to customer collections and counterparty credit conditions. Investment securities increased ¥3.77bn YoY, or 27.3%, to ¥17.57bn and represent 21.0% of total assets. Total equity increased ¥3.50bn YoY to ¥33.04bn, with accumulated other comprehensive income rising to ¥9.24bn. The equity increase was strongly supported by unrealized gains on securities, which improves reported capital but introduces exposure to market-value reversals. Deferred tax liabilities rose to ¥3.40bn from ¥2.17bn, consistent with the larger unrealized valuation gains on securities. Net defined benefit liability was ¥1.03bn and remains a manageable 3.1% of equity.

Notable B/S Changes

Investment securities: +¥3.77bn (+27.3%) to ¥17.57bn — securities now represent 21.0% of total assets; the increase coincided with a ¥2.63bn positive valuation difference on securities, increasing exposure of equity and comprehensive income to market-price movements. Treasury stock: +¥0.56bn (+27.7%, less negative) to -¥0.15bn — the reduced treasury-stock deduction modestly increased equity, but its absolute balance-sheet effect is limited. Accounts receivable: +¥5.16bn (+12.4%) to ¥46.77bn — receivables remain the largest asset category at 55.8% of total assets and require close monitoring given the high-DSO alert. Accounts payable: +¥5.89bn (+17.7%) to ¥39.24bn — the expansion partly funds the higher receivable base, preserving trading-cycle liquidity but increasing counterparty settlement exposure. Total equity: +¥3.50bn (+11.9%) to ¥33.04bn — growth reflects earnings retention and a substantial increase in accumulated other comprehensive income, including securities valuation gains.

Cash Flow Quality

Dividend Sustainability

The company paid an interim dividend of ¥20.0 per share. The calculated interim payout ratio is 24.9% of FY2026 Q3 cumulative net income. Full-year guidance indicates a ¥40.0 per share dividend and FY2026 EPS of ¥101.01, implying a forecast dividend payout ratio of approximately 39.6%. This is below the 60% sustainability benchmark and leaves a meaningful earnings retention buffer. Retained earnings were ¥17.06bn, equivalent to roughly 52% of total equity, supporting balance-sheet capacity for shareholder distributions. The interim dividend increased from ¥17.0 per share in the prior-year period to ¥20.0 per share, a 17.6% increase. Maintaining the full-year ¥40.0 dividend will depend principally on meeting the ¥2.30bn net-income forecast and preserving liquidity through the working-capital cycle.

Risk Assessment

Business risks include Low operating efficiency: the 3.9% EBIT margin is below the 5% concern threshold. The root cause is the low-margin trading model, where modest changes in sales spreads, supplier pricing, or customer pricing can have an outsized effect on operating income. The Q3 margin improvement is positive, but the investment case remains sensitive to whether it can be retained., Low gross margin: gross margin was 14.4%, below the 20% benchmark. This reflects limited gross-profit buffers in chemical trading and increases vulnerability to pricing competition, product-mix shifts, and raw-material price volatility., High receivable days: the quality alert indicates DSO of 255 days. The root cause is a very large receivable balance of ¥46.77bn, equal to 93.3% of Q1-Q3 revenue. This is materially above conventional benchmarks and raises collection, customer-credit, and working-capital funding sensitivity., Chemical-industry exposure: demand conditions, petrochemical and commodity price movements, supplier availability, and customer inventory adjustments can affect both trading volumes and gross spreads..

Financial risks include Refinancing risk: 100% of interest-bearing debt is short term. Although cash covers short-term loans by 2.45x and interest coverage is 55.29x, continued access to short-term funding remains necessary., Securities valuation risk: investment securities increased 27.3% YoY to ¥17.57bn, while positive securities valuation differences contributed ¥2.63bn to other comprehensive income. A reversal in market valuations could reduce equity and comprehensive income., Counterparty and settlement risk: accounts receivable of ¥46.77bn and accounts payable of ¥39.24bn create substantial gross settlement exposure in the ordinary course of trading..

Key concerns include Priority 1 — receivables and collection discipline: the high DSO alert has high potential impact because receivables are the largest asset category and working-capital disruption could quickly pressure liquidity., Priority 2 — margin durability: a 3.9% operating margin leaves limited room for adverse movements in gross spreads or SG&A., Priority 3 — short-term funding rollover: the maturity profile warrants monitoring despite currently solid cash coverage., Priority 4 — earnings composition: dividend income of ¥451mn and the ¥415mn securities-sale gain materially influenced pre-tax earnings, while only the former appears recurring in nature..

Investment Implications

Key takeaways include Core operating performance improved: operating income rose 13.3% YoY and operating margin expanded 37bp to 3.9%., Full-year operating and ordinary-profit guidance appears well supported by Q3 progress rates of 82.7% and 88.8%, respectively., Net-income growth lagged operating growth because gain on sale of investment securities declined ¥290mn YoY., The balance sheet has adequate near-term liquidity, but it is highly dependent on effective receivables management and short-term debt rollover., A forecast dividend payout ratio of approximately 39.6% appears moderate relative to forecast earnings..

Metrics to watch include Gross margin and operating margin, particularly whether the Q3 14.4% and 3.9% levels can be sustained., Accounts receivable, DSO, allowances, and collection performance., Short-term loan balance, cash/short-term-debt coverage, and financing terms., Dividend income and the recurrence of investment-related gains or losses., Market value of investment securities and the associated valuation difference in other comprehensive income., Q4 sales pace versus the remaining ¥20.36bn needed to achieve full-year revenue guidance..

Regarding relative positioning, The company exhibits the balance-sheet and earnings characteristics of a low-margin Japanese chemical trading business: large trade receivable and payable balances, modest operating margins, limited interest-bearing debt, and meaningful investment-income and securities-valuation exposure. Its annualized ROE of 7.5% is below the 8% profitability benchmark, but the Q3 operating-margin improvement and conservative forecast payout ratio are constructive operating and capital-allocation features.